価格表

在庫・価格 : 2024年05月01日 22時24分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
API-2
データシート※最新のデータシートでない場合があります
2151/10 RSDアールアンドディー システムス
R&D Systems, Inc.
10 mg ¥118,000
(未発注)
追加

在庫・価格 : 2024年05月01日 22時24分 現在

API-2

  • 商品コード:2151/10
  • メーカー:RSD
  • 包装:10mg
  • 価格: ¥118,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Tenbaum SP et al. β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat. Med. 2012 Jun;18(6):892-901
Tenbaum SP et al
2012/01/01
Application: Bioassay, Sample Type: Whole Cells PubMed
2 Liu Y et al. AKT hyperactivation confers a Th1 phenotype in thymic Treg cells deficient in TGF-β receptor II signaling. Eur. J. Immunol. 2014 Feb;44(2):521-32
Liu Y et al
2014/01/01
Sample Type: bone marrow PubMed
3 Puig I et al. A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. Clin. Cancer Res. 2013 Dec;19(24):6787-801
Puig I et al
2013/01/01
Sample Type: In Vivo PubMed
4 Kulkarni NN et al. Phenylbutyrate induces cathelicidin expression via the vitamin D receptor: Linkage to inflammatory and growth factor cytokines pathways. Mol. Immunol. 2015 Feb;63(2):530-9
Kulkarni NN et al
2015/01/01
Sample Type: whole cells PubMed
5 Arqu辿s O et al. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin. Cancer Res. 2016 Feb;22(3):644-56
Arqu辿s O et al
2016/01/01
Application: Bioassay,In Vivo, Sample Type: In Vivo,Whole Cells PubMed
  • No.: 1
  • 文献情報:
    Tenbaum SP et al. β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat. Med. 2012 Jun;18(6):892-901
    Tenbaum SP et al
    2012/01/01
  • 備考:
    Application: Bioassay, Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Liu Y et al. AKT hyperactivation confers a Th1 phenotype in thymic Treg cells deficient in TGF-β receptor II signaling. Eur. J. Immunol. 2014 Feb;44(2):521-32
    Liu Y et al
    2014/01/01
  • 備考:
    Sample Type: bone marrow
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Puig I et al. A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. Clin. Cancer Res. 2013 Dec;19(24):6787-801
    Puig I et al
    2013/01/01
  • 備考:
    Sample Type: In Vivo
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Kulkarni NN et al. Phenylbutyrate induces cathelicidin expression via the vitamin D receptor: Linkage to inflammatory and growth factor cytokines pathways. Mol. Immunol. 2015 Feb;63(2):530-9
    Kulkarni NN et al
    2015/01/01
  • 備考:
    Sample Type: whole cells
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Arqu辿s O et al. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin. Cancer Res. 2016 Feb;22(3):644-56
    Arqu辿s O et al
    2016/01/01
  • 備考:
    Application: Bioassay,In Vivo, Sample Type: In Vivo,Whole Cells
  • 参照:
    PubMed